Metformin, the first-line therapy for type 2 diabetes (T2D), decreases hepatic glucose production and reduces fasting plasma glucose levels. Dorzagliatin, a dual-acting orally bioavailable glucokinase activator targeting both the pancreas and liver glucokinase, decreases postprandial glucose in patients with T2D. In this randomized, double-blind, placebo-controlled phase 3 trial, the efficacy and safety of dorzagliatin as an add-on therapy to metformin were assessed in patients with T2D who had inadequate glycemic control using metformin alone. Eligible patients with T2D (n = 767) were randomly assigned to receive dorzagliatin or placebo (1:1 ratio) as an add-on to metformin (1,500 mg per day) for 24 weeks of double-blind treatment, followed by 28 weeks of open-label treatment with dorzagliatin for all patients. The primary efficacy endpoint was the change in glycated hemoglobin (HbA1c) levels from baseline to week 24, and safety was assessed throughout the trial. At week 24, the least-squares mean change from baseline in HbA1c (95% confidence interval (CI)) was −1.02% (−1.11, −0.93) in the dorzagliatin group and −0.36% (−0.45, −0.26) in the placebo group (estimated treatment difference, −0.66%; 95% CI: −0.79, −0.53; P < 0.0001). The incidence of adverse events was similar between groups. There were no severe hypoglycemia events or drug-related serious adverse events in the dorzagliatin and metformin combined therapy group. In patients with T2D who experienced inadequate glycemic control with metformin alone, dorzagliatin resulted in effective glycemic control with good tolerability and safety profile (NCT03141073).

The total scattering cross section in the short wavelength limit is considered in this paper. The problems treated include diffraction of a plane electromagnetic wave by a conducting cylinder (two possible polarizations) or a conducting sphere, acoustic scattering by a rigid sphere, and quantum-mechanical scattering by an impenetrable sphere. The first correction term to the geometric optics result is computed. In each case, this term is proportional to (ka)−2/3. The constant of proportionality depends on the specific geometry.

No abstract

Light-emitting diodes (LEDs) are popularly used as light sources in non-line-of-sight (NLOS) ultraviolet communications (UVC). However, currently reported single-scatter path loss (PL) models of NLOS UVC links assume that the radiant intensity of the light source is uniformly distributed within the beam divergence angle, which cannot well characterize the light emission pattern of LEDs. In this Letter, we propose a single-scatter PL model for LED-based NLOS UVC systems, and the corresponding analytical expression is derived by modeling the LED emission pattern as a Lambertian distribution. Monte Carlo simulations and experimental results are provided to verify the effectiveness of the proposed PL model. Results show that the proposed model can accurately predict PL results in actual situations. The root-mean-square error of the proposed PL model is only about 1 dB in typical scenarios with experimental results as benchmarks. Also, the proposed model is much easier to implement than the currently reported PL model with the light source model of a uniformly distributed emission pattern.

No abstract